Drug-Coated Balloons versus Everolimus-Eluting Stents in Patients with In-Stent Restenosis: A Pair-Wise Meta-Analysis of Randomized Trials
Open Access
- 21 January 2020
- journal article
- review article
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 2020, 1-11
Abstract
Objective. This study aimed to compare the effectiveness of drug-coated balloons (DCB) with everolimus-eluting stents (EES) in the treatment of in-stent restenosis (ISR) and the differential relative effect of DCB in patients with drug-eluting stents (DES)-ISR and bare metal stents (BMS)-ISR. Background. The efficiency and safety of DCB and EES need to be assessed for the treatment of ISR. Methods. A systematic literature search was conducted using PubMed and EMBASE to identify all relevant studies. Angiographic results and clinical events were separately assessed. Subgroup meta-analyses were performed according to the type of restenosed stent. Results. Six randomized trials with 1134 patients were included. The overall pooled outcomes indicated that DCB was associated with lower minimum lumen diameter (mean difference , 95% CI = −0.29 to −0.05, ) and higher target lesion revascularization (risk ratio , 95% CI = 1.36 to 4.18, ) than EES. However, the subgroup meta-analyses showed that DCB was inferior to EES only in DES-ISR patients, with lower minimum lumen diameter (, 95% CI = −0.37 to −0.14, ), higher percent diameter stenosis (, 95% CI = 1.33 to 9.42, ), more binary restenosis (, 95% CI = 1.20 to 3.58, ), and higher incidence of target vessel revascularization (, 95% CI = 1.22 to 3.50, ) and target lesion revascularization (, 95% CI = 1.28 to 4.22, ). No differences in angiographic results and clinical events were found between DCB and EES in BMS-ISR patients. Conclusions. DCB was inferior to EES in DES-ISR and comparable in BMS-ISR in terms of angiographic results and clinical events.
Keywords
Funding Information
- Guizhou Provincial Science and Technology Department ([2019]1197, (2013) 544)
- National Clinical Key Specialty Project Foundation ([2019]1197, (2013) 544)
This publication has 28 references indexed in Scilit:
- Two-Year Outcomes After First- or Second-Generation Drug-Eluting or Bare-Metal Stent Implantation in All-Comer Patients Undergoing Percutaneous Coronary InterventionJACC: Cardiovascular Interventions, 2014
- Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiographyHeart, 2013
- A multicenter randomized comparison of paclitaxel-coated balloon catheter with conventional balloon angioplasty in patients with bare-metal stent restenosis and drug-eluting stent restenosisAmerican Heart Journal, 2013
- Human autopsy study of drug-eluting stents restenosis: histomorphological predictors and neointimal characteristicsEuropean Heart Journal, 2013
- Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trialThe Lancet, 2013
- SeQuent Please World Wide RegistryJACC, 2012
- In-Stent NeoatherosclerosisJACC, 2012
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA StatementJournal of Clinical Epidemiology, 2009
- Treatment of Coronary In-Stent Restenosis with a Paclitaxel-Coated Balloon CatheterNew England Journal of Medicine, 2006
- Paclitaxel Inhibits Arterial Smooth Muscle Cell Proliferation and Migration In Vitro and In Vivo Using Local Drug DeliveryCirculation, 1997